Restoring
Immune Response

Engineering first-in-class therapeutic decoys to block harmful self-targeting antibodies

What we do

Micoy Therapeutics is focused on developing novel therapeutics targeting harmful autoantibodies that induce immunodeficiency by inhibiting type I interferons.

Learn More

Our Science

Our scientists engineered several first-in-class decoy therapies that show promise in blocking these harmful interferon autoantibodies and restoring normal immune functions. Importantly, our decoy therapies are designed to be inert and therefore safely work without causing devastating side-effects.

Learn More

Aging and Autoantibodies

As we age, antibodies that target an individual’s own proteins, also known as autoantibodies, increase and immune responsiveness to foreign pathogens decrease. Some of these autoantibodies block critical immune signaling molecules called type I interferons, making you vulnerable to infection and even cancer.

Anti-interferon autoantibodies can be found in 1-2% of the general population but are more frequent in older adults. Nearly 1 in every 15 individuals over the age of 65 will carry these interferon autoantibodies.

autoantibody increases with age

The Future of our Science

Recent studies indicate that over 100 million individuals have autoantibodies that may decrease the effectiveness of their immune system. Antibodies are normally produced by our immune system to protect our bodies from foreign entities, like viruses. However, in some cases, the body produces autoantibodies that, instead of recognizing a foreign antigen, target and react with our own proteins, tissues and organs.

Increased susceptibility to viral infection

During the pandemic, researchers discovered that nearly 20% of patients who had life-threatening disease or died from COVID-19 had harmful autoantibodies that block crucial proteins called type I interferons. Normally, type I interferons ramp up our antiviral defenses and stop viruses from multiplying and spreading to other tissues.

However, these autoantibodies block your immune response, making you 100 times more likely to end up hospitalized if infected by SARS-CoV-2, influenza, herpes simplex, West Nile virus, cytomegalovirus, varicella-zoster and many more.

Increased susceptibility to tumor growth

Type I interferons are also important in cancer. Many chemotherapy and immunotherapy treatments depend on interferon signaling to activate the immune system and kill tumor cells; however, interferon autoantibodies may work against this process and make anticancer therapies less effective.

Studies linking tumor development and anti-interferon autoantibodies are still ongoing, but their results will have enormous implications for our decoy therapies to help fight cancer by restoring immune response.

Join our campaign

Micoy Therapeutics is seeking investors to join us in developing decoy therapies and restore immune function.

Learn More

760 Parkside Ave, Suite 206
Brooklyn, NY 11226

© Micoy Therapeutics 2025. All rights reserved.

© Micoy Therapeutics 2024.

All rights reserved.